Not yet recruiting
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
NCT07813130· Phase 1· Aruna Bio, Inc.· Source
Contact: Dr. Savitz, Principal Investigator
Recruiting
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
NCT07260916· Weill Medical College of Cornell University· Source
Contact: Atzhiry Paz
Recruiting
CREO - Microwave Ablation Feasibility Study
NCT07817147· Banner Health· Source
Contact: Cecelia Lara
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515· Reprieve Cardiovascular, Inc· Source
Contact: Annemarie Forrest
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· Phase 3· Joseph Broderick, MD· Source
Contact: James Grotta, MD
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Joseph A. Lucci (principal investigator)
Recruiting
StrokeNet Thrombectomy Endovascular Platform
NCT06289985· Medical University of South Carolina· Source
Contact: Jordan Elm
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Active, not recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031· BrioHealth Solutions, Inc.· Source
Recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
NCT05907629· Yale University· Source
Contact: AQUINO HERNANDEZ
Recruiting
Strategy for Improving Stroke Treatment Response
NCT05948566· Phase 2· Translational Sciences, Inc.· Source
Contact: Prasen Marella
Active, not recruiting
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT05538897· Phase 1/2· National Cancer Institute (NCI)· Source
Recruiting
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05646316· Phase 3· NRG Oncology· Source
Contact: Joseph A. Lucci (principal investigator)
Active, not recruiting
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172· Phase 3· University of Florida· Source
Recruiting
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697· Yale University· Source
Contact: Sean Savitz, MD
Active, not recruiting
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· Phase 3· NRG Oncology· Source
Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709· Impulse Dynamics· Source
Contact: Lawana Self
Active, not recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883· Phase 3· Joseph Broderick, MD· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Joseph A. Lucci (principal investigator)
Active, not recruiting
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046· Phase 3· Yale University· Source
Contact: Andrew Barreto, MD
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03994796· Phase 2· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
NCT03115333· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT02466971· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014· Phase 2· Alliance for Clinical Trials in Oncology· Source
Contact: Jay-Jiguang Zhu (principal investigator)
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT02152982· Phase 2/3· National Cancer Institute (NCI)· Source
Active, not recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Source
Active, not recruiting
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source